Successful treatment of low‐risk myelodysplastic syndrome‐related anemia in patients with chronic kidney disease with daprodustat: A report of two cases

Abstract Anemia is a major clinical manifestation seen in myelodysplastic syndromes (MDS). Treatment options for anemia in low‐risk MDS are limited. Especially, oral medication which is uniformly effective for anemia in low‐risk MDS is required. Hypoxia‐inducible factor (HIF) prolyl hydroxylase (HIF‐PH) inhibitors, such as daprodustat, are oral tablets effective for renal anemia. Pharmacological restoration of HIF activity by HIF‐PH inhibitors may be beneficial for MDS‐related anemia as well. Yet, their efficacy and safety against low‐risk MDS are unclear. Here, we report two cases of low‐risk MDS complicated with chronic kidney disease whose anemia responded to daprodustat treatment.